読み込み中
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
前日終値
$21.51
+$0.32 · +1.51%
日中の時刻はETです。市場データは遅延する場合があります。
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
日中レンジ
現在 $21.51
52週レンジ
現在 $21.51
日中の時刻はETです。市場データは遅延する場合があります。
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
日中レンジ
現在 $21.51
52週レンジ
現在 $21.51
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1448.63万0.00%2.3兆 USD0.03%$371.57-1.76%
Vanguard Extended Market ETFVXF508.36万0.01%912億 USD0.05%$230.39-2.14%
Schwab U.S. Small-Cap ETFSCHA242.02万0.01%220.41億 USD0.03%$32.99-1.58%
Fidelity Fundamental Small-Mid Cap ETFFFSM115.86万0.08%14.4億 USD0.43%$34.10-1.70%
Fidelity Nasdaq Composite Index ETFONEQ36.88万—109.4億 USD0.21%$100.25-2.84%
Schwab U.S. Broad Market ETFSCHB29.46万0.00%442.31億 USD0.03%$29.07-1.82%
Fidelity Disruptive Medicine ETFFMED27.12万0.50%5231万 USD0.50%$32.4109-3.11%
Vanguard Russell 2000 ETFVTWO16万0.00%173億 USD0.06%$112.85-1.63%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAFidelity Fundamental Small-Mid Cap ETFFFSMFidelity Nasdaq Composite Index ETFONEQSchwab U.S. Broad Market ETFSCHBFidelity Disruptive Medicine ETFFMEDVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
